arsenic trioxide has been researched along with Cardiac Diseases in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmadimoghaddam, D; Ataei, S; Gholami, A; Nili-Ahmadabadi, A; Omidifar, N | 1 |
| Chandrabhatla, AS; Christiansen, SL; Holmes, JW; Nelson, AR; Saucerman, JJ; Zeigler, AC | 1 |
| Choi, KC; Kim, CW | 1 |
| Arathi, P; Binu, P; Nair, RH; Vineetha, RC | 1 |
| Raghu, KG; Vineetha, VP | 1 |
| Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MV | 1 |
| Bradley, TP; Budman, DR; Kritharis, A | 1 |
| Aki, T; Funakoshi, T; Uemura, K; Unuma, K; Watanabe, M | 1 |
| Feusner, JH; Gregory, J; Kutny, MA | 1 |
| Bowen, D; Burnett, AK; Cahalin, P; Craig, J; Hills, RK; Hunter, A; Kell, J; McMullin, MF; Milligan, D; Russell, N; Wheatley, K; Yin, J | 1 |
| Kang, YJ; Li, Y; Sun, X; Wang, L; Zhou, Z | 1 |
| Ewer, MS; Jones, RL | 1 |
| Chai, LM; Chen, JX; Du, ZM; Li, GY; Liu, Y; Lu, YJ; Yang, BF; Zhang, Y; Zhao, XY | 1 |
| Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Satoh, H; Shigeno, K; Shinjo, K; Takeshita, A; Terada, H; Yoshida, H | 1 |
5 review(s) available for arsenic trioxide and Cardiac Diseases
| Article | Year |
|---|---|
Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cardiotoxicity; Cardiovascular System; Doxorubicin; Endoplasmic Reticulum Stress; Heart Diseases; Humans; Mitochondria; Mitochondria, Heart; Myocytes, Cardiac; Oxidative Stress; Reactive Oxygen Species | 2021 |
An Overview on Arsenic Trioxide-Induced Cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Calcium Signaling; Cardiotoxicity; Heart Diseases; Heart Rate; Humans; Mitochondria, Heart; Myocytes, Cardiac; Oxidative Stress; Reactive Oxygen Species; Risk Assessment; Risk Factors; Tissue Distribution | 2019 |
The evolving use of arsenic in pharmacotherapy of malignant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome | 2013 |
Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin | 2014 |
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiovascular Diseases; Heart Diseases; Humans; Interferons; Interleukin-2; Neoplasms; Oxides; Stilbenes; Tretinoin | 2006 |
1 trial(s) available for arsenic trioxide and Cardiac Diseases
| Article | Year |
|---|---|
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome | 2011 |
8 other study(ies) available for arsenic trioxide and Cardiac Diseases
| Article | Year |
|---|---|
Pentoxifylline Attenuates Arsenic Trioxide-Induced Cardiac Oxidative Damage in Mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Cardiotoxicity; Heart Diseases; Lipid Peroxidation; Male; Malondialdehyde; Mice; Necrosis; Nitric Oxide; Oxidative Stress; Pentoxifylline; Vasodilator Agents | 2021 |
Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Arsenic Trioxide; Biphenyl Compounds; Computer Simulation; Drug Combinations; Fibroblasts; Fibrosis; Heart Diseases; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Models, Animal; Network Pharmacology; Pyrazoles; Quaternary Ammonium Compounds; Quinolines; Rats; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad3 Protein; Thioctic Acid; Valsartan | 2021 |
L-ascorbic acid and α-tocopherol attenuate arsenic trioxide-induced toxicity in H9c2 cardiomyocytes by the activation of Nrf2 and Bcl2 transcription factors.
Topics: alpha-Tocopherol; Animals; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cardiotoxicity; Cell Line; Cytoprotection; Heart Diseases; Membrane Potential, Mitochondrial; Mitochondria, Heart; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Rats; Signal Transduction | 2018 |
Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Body Burden; Catalase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Heart Diseases; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Male; Myocytes, Cardiac; Oxides; Rats; Rats, Wistar; Superoxide Dismutase; Time Factors | 2013 |
Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Heart Diseases; Homeostasis; Immunoprecipitation; Lysosomes; Membrane Potential, Mitochondrial; Mice; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Oxides; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin; Ubiquitin-Protein Ligases; Voltage-Dependent Anion Channel 1 | 2014 |
Myocardial toxicity of arsenic trioxide in a mouse model.
Topics: Adrenergic beta-Agonists; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Body Weight; Caspase 3; Caspases; Heart Diseases; Immunoenzyme Techniques; Isoproterenol; Mice; Mice, Inbred Strains; Microscopy, Electron; Myocardium; Organ Size; Oxides; Signal Transduction; Ventricular Function, Left | 2002 |
Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Calcium; Caspase 3; Cell Survival; Cytoplasm; Electrocardiography; Female; Heart Diseases; In Situ Nick-End Labeling; In Vitro Techniques; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Myocytes, Cardiac; Oxidative Stress; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes | 2008 |
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Monitoring; Electrocardiography; Female; Heart; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Remission Induction; Tretinoin | 2002 |